ANTXR1 and neoplasm: Fernando et al. used a tTF-fused antibody-conjugate, targeting the integrin receptor TEM8 (tumor endothelial marker 8), to disrupt tumor vessels in a xenograft model of human colorectal carcinoma and found high targeting specificity allowing inhibition of tumor growth but without necrosis [64].